Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101

Summary

The purpose of this study is evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of of fully human anti - VEGF monoclonal antibody LY00101 and explore the potential prognostic and predictive biomarkers. This study will not take into account the results of molecular-genetic tests of patients enrolled in the study

Timeline

Start

2019-04-03

Primary completion

2020-06

Completion

2020-08

Outcome

Outcome not reported

Stopped (Enrollment): “Unable to recruit individuals for the study”

Drugs

Indications